Lanthanide conjugates as versatile instruments for therapy and diagnostics

Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form

PURPOSE

With the growing interest in exploring radiolanthanides for nuclear medicine applications, the question arises as to whether they are generally interchangeable without affecting a biomolecule's pharmacokinetic properties. The goal of this study was to investigate similarities and differences of four (radio)lanthanides simultaneously applied as complexes of biomolecules or in ionic form.

METHODS

Inductively coupled plasma mass spectrometry (ICP-MS) was employed for the simultaneous detection of four lanthanides (Ln = lutetium, terbium, gadolinium and europium) in biological samples. In vitro tumor cell uptake and in vivo biodistribution studies were performed with Ln-DOTATATE, Ln-DOTA-LM3, Ln-PSMA-617 and Ln-OxFol-1. AR42J cells, PC-3 PIP cells and KB cells expressing the somatostatin receptor, the prostate-specific membrane antigen and the folate receptor, respectively, were used in vitro as well as to obtain the respective tumor mouse models for in vivo studies. The distribution of lanthanides in ionic form was investigated in immunocompetent mice. Dual-isotope SPECT/CT imaging studies were performed with mice administered with the radiolabeled biomolecules or chloride salts of lutetium-177 and terbium-161.

RESULTS

Similar in vitro cell uptake was observed for all four lanthanide complexes of each biomolecule into the respective tumor cell lines. AR42J tumor uptake of Ln-DOTATATE and Ln-DOTA-LM3 in mice showed similar values for all lanthanide complexes (3.8‒5.1% ID/g and 4.5‒5.0% ID/g; 1 h p.i., respectively). Accumulation of Ln-PSMA-617 in PC-3 PIP tumors (24-25% ID/g; 1 h p.i.) and of Ln-OxFol-1 in KB tumors (28-31% ID/g; 24 h p.i.) were also equal for the four lanthanide complexes of each biomolecule. After injection of lanthanide chloride salts (LnCl3; Ln = natLu, natTb, natGd, natEu), the liver uptake was different for each metal (~ 12% ID/g, ~ 22% ID/g, ~ 31% ID/g and ~ 37% ID/g; 24 h p.i., respectively) which could be ascribed to the radii of the respective lanthanide ions. In the bones, accumulation was considerably higher for lutetium than for other lanthanides (25 ± 5% ID/g vs. 14‒15% ID/g; 24 h p.i.). These data were confirmed visually by 177Lu/161Tb-based dual-isotope SPECT/CT images.

CONCLUSIONS

The presented study confirmed similar properties of Ln-complexes, suggesting that lutetium-177 can be replaced by other radiolanthanides, most probably without affecting the tissue distribution profile of the resultant radiopharmaceuticals. On the other hand, the different radii of the lanthanide ions affected their uptake and resorption mechanisms in liver and bones when injected in uncomplexed form.

Investigation of Ln3+ complexation by a DOTA derivative substituted by an imidazothiadiazole: synthesis, solution structure, luminescence and relaxation properties

We investigated the coordination properties of original macrocyclic Ln3+ complexes comprising an imidazothiadiazole heterocycle. The thermodynamic stability of the Gd3+ complex was determined by a combination of potentiometric and photophysical measurements. The kinetic inertness was assessed in highly acidic media. The solution structure of the Ln3+ complex was unambiguously determined by a set of photophysical measurements and 1H, 13C, 89Y NMR data in combination with DFT calculations, which proved coordination of the heterocycle to Ln3+. The ability of the imidazothiadiazole moiety to sensitize Tb3+ luminescence was investigated. Finally, the relaxation properties were investigated by recording 1H nuclear magnetic relaxation dispersion (NMRD) profiles and 17O measurements. The water exchange rate is similar to that of GdDOTA as the less negative charge of the ligand is compensated for by the presence of a bulky heterocycle. Relaxivity is constant over a large range of pH values, demonstrating the favorable properties of the complex for imaging purposes.

Recent advances of lanthanide nanomaterials in Tumor NIR fluorescence detection and treatment

Lanthanide nanomaterials have garnered significant attention from researchers among the main near-infrared (NIR) fluorescent nanomaterials due to their excellent chemical and fluorescence stability, narrow emission band, adjustable luminescence color, and long lifetime. In recent years, with the preparation, functional modification, and fluorescence improvement of lanthanide materials, great progress has been made in their application in the biomedical field. This review focuses on the latest progress of lanthanide nanomaterials in tumor diagnosis and treatment, as well as the interaction mechanism between fluorescence and biological tissues. We introduce a set of efficient strategies for improving the fluorescence properties of lanthanide nanomaterials and discuss some representative in-depth research work in detail, showcasing their superiority in early detection of ultra-small tumors, phototherapy, and real-time guidance for surgical resection. However, lanthanide nanomaterials have only realized a portion of their potential in tumor applications so far. Therefore, we discuss promising methods for further improving the performance of lanthanide nanomaterials and their future development directions.

Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy

Immunotherapy is among the most effective approaches for treating cancer. One of the key aspects for successful immunotherapy is to achieve a strong and stable antitumor immune response. Modern immune checkpoint therapy demonstrates that cancer can be defeated. However, it also points out the weaknesses of immunotherapy, as not all tumors respond to therapy and the co-administration of different immunomodulators may be severely limited due to their systemic toxicity. Nevertheless, there is an established way through which to increase the immunogenicity of immunotherapy-by the use of adjuvants. These enhance the immune response without inducing such severe adverse effects. One of the most well-known and studied adjuvant strategies to improve immunotherapy efficacy is the use of metal-based compounds, in more modern implementation-metal-based nanoparticles (MNPs), which are exogenous agents that act as danger signals. Adding innate immune activation to the main action of an immunomodulator makes it capable of eliciting a robust anti-cancer immune response. The use of an adjuvant has the peculiarity of a local administration of the drug, which positively affects its safety. In this review, we will consider the use of MNPs as low-toxicity adjuvants for cancer immunotherapy, which could provide an abscopal effect when administered locally.

Effect of the aromatic substituent on the para-position of pyridine-bis(oxazoline) sensitizers on the emission efficiency of their EuIII and TbIII complexes

Two efficient lanthanide ion sensitizers 2,6-bis(oxazoline)-4-phenyl-pyridine (PyboxPh, 1) and 2,6-bis(oxazoline)-4-thiophen-2-yl-pyridine (Pybox2Th, 2) were synthesized. 1 crystallizes in the monoclinic space group P21/c with cell parameters a = 16.3794(4) Å, b = 7.2856(2) Å, c = 11.7073(3) Å, β = 97.229(1)° and V = 1385.97(6) Å3. 2 crystallizes in the monoclinic space group P21/n with cell parameters a = 5.9472(2), b = 16.0747(6), c = 14.3716(5) Å, β = 93.503(1)° and V = 1371.35(8) Å3. Photophysical characterization of 1 shows that its triplet state energy is located at 22 250 cm-1 and efficient energy transfer is observed for EuIII and TbIII. Solutions of [Ln(PyboxPh)3]3+ in dichloromethane display an emission efficiency of 37.2% for Ln[double bond, length as m-dash]Eu and 24.0% for Ln[double bond, length as m-dash]Tb. The excited state lifetimes for EuIII and TbIII are 2.227 ms and 723 μs, respectively. The triplet state energy of 2 is located at 19 280 cm-1 and is therefore too low to efficiently sensitize TbIII emission. However, the sensitization of EuIII is effective, with an emission quantum yield of 14.5% and an excited state lifetime of 714 μs. This shows that the derivatization of the chelator is strongly influenced by the aromatic substituents on the para-position of the pyridine ring. New isostructural 1 : 1 complexes of PyboxPh with EuIII (3) and TbIII (4) were also isolated and crystallize in the triclinic space group P1[combining macron] with cell parameters a = 9.1845(2) Å, b = 10.3327(2) Å, c = 11.9654(2) Å, α = 98.419(1)°, β = 108.109(1)°, γ = 91.791(1)°, V = 1064.08(4) Å3 and a = 7.8052(1) Å, b = 11.8910(1) Å, c = 14.2668(2) Å, α = 72.557(1)°, β = 86.355(1)°, γ = 77.223(1)°, V = 1231.95(3) Å3, respectively.